
AstraZeneca Shares Rise After Beating Q2 Expectations, Reconfirming 2030 Outlook
AstraZeneca's Q2 net profit rose 2% to $2.51 billion, beating analyst expectations, driven by strong cancer medicine sales. Shares rose 1.4% in European trading despite a recent trial failure, with the company reconfirming its $80bn 2030 revenue goal.

















